Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Glucotrack (GCTK) announced the successful completion of its first in human clinical study, marking a significant milestone in continuous ...

Here is why companies split their stocks and why it matters. Plus, upcoming stock splits from Southern Copper, cannabis ETFs, ...

Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies ...

Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ:GCTK), a medical device company specializing in diabetes care technology, has announced a 1-for-20 reverse stock split of its issued and outstanding common ...

RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization ...